Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001346 | 0.83 | NPC1 (0.39) | CTSANPC1NAMPTITKUBE2M | |
| SCHEMBL12678009 | 0.82 | P2RX7 (0.53) | P2RX7GRM5CTSANPC1RAB9A | |
| SCHEMBL8575197 | 0.78 | P2RX7 (0.55) | P2RX7GRM5CTSARAB9ACYP1A2 | |
| SCHEMBL7655284 | 0.74 | CYP1A2 (0.39) | P2RX7NPC1RAB9ACYP1A2MEN1 | |
| SCHEMBL10085785 | 0.73 | P2RX7 (0.54) | P2RX7GRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL14875787 | 0.73 | P2RX7 (0.50) | P2RX7GRM5CTSANPC1RAB9A | |
| SCHEMBL7651990 | 0.73 | ROCK2 (0.39) | NPC1RAB9ACYP1A2MEN1KMT2A | |
| SCHEMBL3739445 | 0.72 | P2RX7 (0.49) | P2RX7GRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL20460420 | 0.72 | JUN (0.35) | NPC1NAMPTITKMEN1KMT2A | |
| SCHEMBL7659676 | 0.72 | CYP1A2 (0.37) | NPC1RAB9ACYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | P2RX7 1522/4885GRM5 1519/4885SORT1 4113/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | P2RX7 4037/4885GRM5 3906/4885SORT1 4246/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | P2RX7 1522/4885GRM5 1519/4885SORT1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.